![](https://assets.ipopremium.in/img/logo-dark.png)
Ambey Laboratories Limited (NSE SME)
Jul 4, 2024 - Jul 8, 2024
Price | ₹65 - ₹68 |
Premium | ₹28 |
---|---|
Lot size | 2000 |
Allotment | Jul 9, 2024 |
Listing | Jul 11, 2024 |
Category | Lot(s) | Qty | Amount | Reserved |
---|---|---|---|---|
Retail | 1 | 2000 | 136000 | 1092 |
HNI | 2 | 4000 | 272000 | 468 |
Last updated on 08-Jul-2024 17:03:02
Category | Offered | Applied | Times |
---|---|---|---|
QIB | 1252000 | 77496000 | 61.9 |
NIB | 936000 | 196686000 | 210.13 |
RETAIL | 2184000 | 424088000 | 194.18 |
Total | 4372000 | 698270000 | 159.71 |
Retail Apps | 212044 | © IPO Premium |
HNI Interest Cost Per Share (7 Days) | |||||
---|---|---|---|---|---|
@7% ₹19.18 | @8% ₹21.92 | @9% ₹24.66 | @10% ₹27.4 | @11% ₹30.14 | @12% ₹32.88 |
Ambey Laboratories IPO Reservation
Investor Category | Shares Offered | No. of Shares |
---|---|---|
Retail | 33.24% | 2184000 |
NII (HNI) | 14.25% | 936000 |
QIB | 19.05% | 1252000 |
Anchor | 28.44% | 1868000 |
Market Maker | 5.02% | 330000 |
Total | 100.00% | 6570000 |
Ambey Laboratories IPO Details
Total Issue Size | 6,570,000 shares (aggregating up to ₹[44.68] Cr) |
Fresh Issue | 6,258,000 shares (aggregating up to ₹[42.55] Cr) |
Offer for Sale | 312,000 shares of ₹10 (aggregating up to ₹[2.12 ] Cr) |
Issue Type | Book Built Issue IPO |
Listing At | NSE SME |
Share holding pre issue | 18,688,819 |
Share holding post issue | 25,240,819 |
Market Maker portion | 330,000 shares Nikunj Stock Brokers |
Key Performance Indicators
KPI | Jan-24 | Mar-23 | Mar-22 |
---|---|---|---|
ROE | 20.80% | 21.40% | 63.82% |
ROCE | 13.14% | 12.75% | 12.53% |
D/E | 0.58 | 0.58 | 0.95 |
RONW | 20.80% | 21.40% | 63.82% |
EPS Diluted | 3.33 | 2.57 | 7.08 |
P/E Pre IPO | 27.81 | ||
P/E Post IPO | 23.54 |
Financial Statement (Restated)
Period Ended | Jan-24 | Mar-23 | Mar-22 | Mar-21 |
---|---|---|---|---|
Assets | 8,620.84 | 5,761.85 | 5,592.94 | 4,461.80 |
Revenue | 10,043.69 | 10,743.47 | 8,511.19 | 8,241.54 |
Profit After Tax | 607.73 | 456.93 | 357.47 | 1,033.67 |
Net Worth | 3,431.34 | 2,363.60 | 1,906.67 | -786.39 |
Reserves and Surplus | 1,562.46 | 588.66 | 131.73 | -1,275.74 |
Total Borrowing | 2,005.44 | 1,365.22 | 1,804.86 | 3,292.98 |
Amount in Lakhs |
About Company
Ambey Laboratories, incorporated in 1985, specializes in manufacturing agrochemical products for crop protection and has been a stalwart in the agrochemical sector for almost four decades. The company is renowned for producing and supplying 2,4-D base chemicals, operating from its ISO 9001:2015 and ISO 14001:2015 certified manufacturing facility in Behror, Rajasthan. Its product lineup includes 2,4-D Acid 98% TC, 2,4-D Sodium 95% SP, 2,4-D Amine 866 | 720 | 480g/l SL, 2,4-D Ethyl Hexyl Ester 96% TC, 2,4-D Ethyl Ester 96% TC, Chlorpyriphos 97%TC / 20%EC / 50%EC, Thiamethoxam 96%TC / 25%WG / 75%SG, Pretilachlor 95%TC / 50%EC / 37%EW, Metribuzin 97%TC / 70%WS, Hexaconazole 92%TC / 5%SC / 5%EC / 10%EC, and Metalaxyl 98%TC / 35%WS. With a workforce of 220 employees as of October 31, 2023, Ambey Laboratories serves a diverse customer base, including large corporates like Aromatic Rasayan Private Limited, JR Jindal Infraprojects Private Limited, and SC Formulator Co. Ltd.
Strength Factors
Prime Location of our Manufacturing Facility: Ambey Laboratories' manufacturing facility in Behror, Rajasthan, is strategically located, enhancing logistical efficiency and accessibility to key markets.
Quality Assurance and Standards: The company is committed to maintaining high standards of quality, evidenced by its ISO 9001:2015 and ISO 14001:2015 certifications, ensuring the production of reliable and environmentally responsible agrochemical products.
Cordial Relationships with our Suppliers: Ambey Laboratories has established strong, cooperative relationships with its suppliers, which ensures a steady supply of high-quality raw materials and contributes to the company's overall operational stability and success.
Risk Factors
Frozen Promoter Demat Account: The promoter's demat account has been frozen as per an SEBI letter dated 11.02.2021, with the reasons and duration of the freeze unclear due to the unavailability of the letter, potentially impacting corporate governance and financial operations.
Client Dependency: A substantial portion of the company's revenue depends on a few key clients, and the loss of any major client could materially and adversely affect business operations and profitability.
Business Seasonality: The company's operations are subject to seasonal fluctuations, which can impact production schedules, inventory management, and overall financial performance.
Fast Track Finsec Pvt Ltd
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: ambeylab.ipo@Linkintime.co.in
Website: https://linkintime.co.in/initial_offer/public-issues.html